Drugs Made In America Acquisition II Corp
DMIIBuild a strategy around DMII
Drugs Made In America Acquisition II Corp AI Insights
Informational only. Not investment advice.Snapshot
- Pre-revenue SPAC with 502M raised via IPO, trading at 0.61x book value (294M market cap vs 483M equity) - 39% discount to NAV[P/B Ratio]
- Cash of 315K vs 501M trust assets implies 500M+ held in trust pending deal - minimal operating liquidity[Cash and Equivalents]
- Zero debt with 219K working capital and 156K annual G&A burn - ~18 months runway at current rate[Working Capital]
Watch Triggers
- Total Revenue: Any revenue recognition — Signals business combination completed - fundamentally different investment
- Cash and Equivalents: Increase above 1M or trust redemption activity — Trust movement indicates deal progress or liquidation timeline
- Volume: Sustained increase above 100K daily — May signal deal announcement leak or institutional interest
Bull Case
39% discount to NAV (0.61x P/B) provides downside protection - liquidation would return ~1.64x current price assuming full trust value
502M war chest targeting US pharma manufacturing aligns with reshoring trend and CHIPS-style drug security legislation
Bear Case
Zero operating history, no identified target, and 11.7K daily volume creates severe illiquidity risk - may not exit at NAV
SPAC sponsor dilution typically 20%+ on deal completion - current NAV discount may not survive merger economics
Bull vs Bear Balance
AI-generated sentiment analysis based on fundamental metrics and market conditions.
Leverage DMII's top insights and create a custom strategy based on them in seconds. Our AI editor does it all — in one click.
Forward Thesis
SPAC will either complete pharma acquisition or liquidate at ~NAV within 12-24 months
- 502M trust capital seeking US drug manufacturing target
- Typical SPAC deadline forces action within 24 months
- Healthcare/pharma focus per company name
Valuation Context
Caveats
Public Strategies Rankings
See how Drugs Made In America Acquisition II Corp ranks across different investment strategies.
Leverage DMII's top insights and create a custom strategy in seconds. Our AI editor does it all — in one click.
DMII Fundamentals
| Metric | Value | YoY Growth | Industry Percentile |
|---|---|---|---|
$297.53M | — | ||
$297.21M | — | ||
0.00 | — | ||
$0 | — | ||
$0.00 | — | ||
0% | — | ||
0% | — | ||
$0 | — | ||
0% | — | ||
Beta 5Y (Monthly) | unknown | — |
DMII Dividend History
DMII Stock Splits
DMII SEC Filings
| Filing Date | Report Date | Report Type | Filing Link |
|---|---|---|---|
11/18/25 | 09/30/25 | 10-Q | |
09/25/25 | 06/30/25 | 424B4 | |
07/21/25 | 03/31/25 | S-1 |